The following characteristics of HAIC render it a suitable candidate for combination with other antineoplastic agents for advanced HCC: it is associated with fewer systemic adverse events compared with intravenous chemotherapy, and its cytotoxic mechanism is distinct from those of other HCC therapeutic modalities.、、
HAIC的以下特点使其成为与其他抗肿瘤药物联合治疗晚期HCC的合适候选药物：与静脉化疗相比，它与更少的全身性不良事件相关，其细胞毒性机制不同于其他HCC治疗方式。
Several studies have explored potential HAIC-based combination strategies (Table 2).
一些研究已经探索了潜在的基于HAIC的组合策略（表）。
|
文献 |
研究设计 |
病例数 |
方案 |
CP-B（%） |
HBV（%） |
PVT（%） |
EHS（%） |
ORR（%） |
OS（月） |
P值 |
|
INFα |
Sakon et al. [42] |
Phase 2
single arm
VP3–4, no EHS
|
11 |
5-FU 450–500 mg/m2,
Days 1–5
INF-α5 MU qW1,3,5 |
54.5 |
36.4 |
100 |
0 |
72.7 |
8.0 |
|
|
Eun et al. [43] |
Retrospective
single arm |
31 |
HAIC: 5-FU 750 mg/m2,
cisplatin 25 mg/m2, Days 1–4 |
19.4 |
83.9 |
100 |
NR |
19.4 |
4.0 |
0.353 |
|
21 |
INF-α 3MU Days 1–4, then QOD HAIC alone: 5-FU 750 mg/m2,
cisplatin 25 mg/m2, Days 1–4 |
19.0 |
85.7 |
100 |
NR |
42.9 |
7.0 |
|
索拉非尼 |
Ikeda et al. [44] |
Randomized
Phase 2
CPS-A, B7 |
65 |
Cisplatin 65 mg/m2, Day 1
Every 4–6 weeks
plus sorafenib |
12.3 |
33.8 |
61.5 |
29.2 |
21.7 |
10.8 |
0.031 |
|
41 |
索拉非尼 |
4.9 |
22.0 |
41.5 |
31.7 |
7.3 |
8.7 |
|
Kudo et al. [45] |
Phase 3
CPS-A, B7 |
102 |
Cisplatin 20 mg/m2, Day 1, 8
5-FU 330 mg/m2 Days 1–5,
8–12 (every 4 weeks)
Plus sorafenib |
11.7 |
25.5 |
56.9 |
26.5 |
36.0（mRECIST） |
11.8 |
0.995 |
|
103 |
索拉非尼 |
9.7 |
21.4 |
62.1 |
25.2 |
18.0（mRECIST） |
11.5 |
|
Zhao et al. [46] |
Retrospective
CPS-A |
46 |
Oxaliplatin 85 mg/m2, Day 1
(every 3 weeks)
Plus sorafenib |
0 |
84.8 |
89.1
(VP3–4) |
19.6 |
34.8 |
9.4 |
＜0.01 |
|
58 |
索拉非尼 |
0 |
89.7 |
84.5 |
27.6 |
1.7 |
4.8 |
|
He et al. [47] |
Phase 3
PVT
CPS-A |
125 |
mFOLFOX 6, Days 1–3
(every 3 weeks)
Plus sorafenib |
0 |
80.0 |
100 |
30.4 |
40.8 |
13.4 |
＜0.01 |
|
122 |
索拉非尼 |
0 |
81.1 |
100 |
34.4 |
2.5 |
7.1 |
|
仑伐替尼 |
Mai et al. [48] |
Retrospective
Single arm |
24 |
mFOLFOX 6, Days 1–3
(every 3 weeks)
plus lenvatinib |
16.7 |
10.3 |
NR |
NR |
58.3 |
12 m 75% |
|
|
基于免疫 |
Gu et al. [49] |
Retrospective
Single arm |
6 |
mFOLFOX 6, Days 1–3
(every 3 weeks)
阿帕替尼(Apatinib) 250 mg QD
(since D8)
Toripalimab 240 mg D4, |
0 |
NR |
100 |
33.3 |
100 |
NR |
|
|
He et al. [50] |
Retrospective |
71 |
mFOLFOX 6, Days 1–3
Lenvatinib
国产特瑞普利单抗
(Toripalimab) 240 mg per session |
0 |
87.3 |
77.5 |
22.5 |
59.2 |
NR |
<0.001 |
|
86 |
Lenvatinib |
0 |
90.7 |
72.1 |
29.1 |
9.3 |
11 |
|
放疗 |
Han et al. [51] |
Prospective
Single arm
PVT |
40 |
5-FU 500 mg/m2, Days 1–3
cisplatin 60 mg/m2, Day 2
plus RT |
0 |
92.5 |
100 |
NR |
45 |
13.1 |
|
|
Katamura et al. [52] |
Retrospective
PVT |
16 |
5-FU 500 mg/m2, Days 1–5
plus RT |
25.0 |
25.0 |
100 |
37.5 |
75.0 |
7.5 |
0.871 |
|
16 |
5-FU 500 mg/m2, Days 1–5 |
18.8 |
31.3 |
100 |
25.0 |
25.0 |
7.9 |
|
Fujino et al. [53] |
Retrospective
PVT, VP3–4
No EHS |
41 |
cisplatin 20 mg/m2, Day 1, 8
5-FU 330 mg/m2
Days 1–5, 8–12
INF-α: recombinant 3MU
or natural 5MU
plus RT |
19.5 |
26.5 |
100 |
0 |
56.1 |
12.1 |
0.309 |
|
42 |
HAIC plus INF-α as above |
23.8 |
23.8 |
100 |
0 |
33.3 |
7.2 |
|
Kodama et al. [54] |
Retrospective
PVT and CPS-A, B7 |
68 |
Cisplatin 20 mg/m2,
day 1, 8
5-FU 330 mg/m2,
Days 1–5, 8–12
(5-FU only in cycle 1–2)
plus RT |
20.6 |
29.4 |
100 |
19.1 |
27.8 |
9.9 |
0.02 |
|
40 |
索拉非尼 |
12.5 |
42.5 |
100 |
40.0 |
6.7 |
5.3 |
|
